Literature DB >> 22672335

Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway.

Frédéric Ancot1, Catherine Leroy, Ghaffar Muharram, Jonathan Lefebvre, Jérôme Vicogne, Arnaud Lemiere, Zoulika Kherrouche, Bénédicte Foveau, Albin Pourtier, Oleg Melnyk, Silvia Giordano, Anne Chotteau-Lelievre, David Tulasne.   

Abstract

The receptor tyrosine kinase Met and its ligand, the hepatocyte growth factor/scatter factor, are essential for embryonic development, whereas deregulation of Met signaling pathways is associated with tumorigenesis and metastasis. The presenilin-regulated intramembrane proteolysis (PS-RIP) is involved in ligand-independent downregulation of Met. This proteolytic process involves shedding of the Met extracellular domain followed by γ-secretase cleavage, generating labile intracellular fragments degraded by the proteasome. We demonstrate here that upon shedding both generated Met N- and C-terminal fragments are degraded directly in the lysosome, with C-terminal fragments escaping γ-secretase cleavage. PS-RIP and lysosomal degradation are complementary, because their simultaneous inhibition induces synergistic accumulation of fragments. Met N-terminal fragments associate with the high-affinity domain of HGF/SF, confirming its decoy activity which could be reduced through their routing to the lysosome at the expense of extracellular release. Finally, the DN30 monoclonal antibody inducing Met shedding promotes receptor degradation through induction of both PS-RIP and the lysosomal pathway. Thus, we demonstrate that Met shedding initiates a novel lysosomal degradation which participates to ligand-independent downregulation of the receptor.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22672335     DOI: 10.1111/j.1600-0854.2012.01384.x

Source DB:  PubMed          Journal:  Traffic        ISSN: 1398-9219            Impact factor:   6.215


  18 in total

1.  Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion.

Authors:  Mireia Náger; Maria Santacana; Deepshikha Bhardwaj; Joan Valls; Isidre Ferrer; Pere Nogués; Carles Cantí; Judit Herreros
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.

Authors:  Kyung Chan Park; Bekesho Geleta; Lionel Yi Wen Leck; Jasmina Paluncic; Shannon Chiang; Patric J Jansson; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2019-11-19       Impact factor: 5.157

3.  One-pot chemical synthesis of small ubiquitin-like modifier protein-peptide conjugates using bis(2-sulfanylethyl)amido peptide latent thioester surrogates.

Authors:  Emmanuelle Boll; Hervé Drobecq; Nathalie Ollivier; Annick Blanpain; Laurent Raibaut; Rémi Desmet; Jérôme Vicogne; Oleg Melnyk
Journal:  Nat Protoc       Date:  2015-01-15       Impact factor: 13.491

4.  Activation of the cAMP/PKA pathway induces UT-A1 urea transporter monoubiquitination and targets it for lysosomal degradation.

Authors:  Hua Su; Minguang Chen; Jeff M Sands; Guangping Chen
Journal:  Am J Physiol Renal Physiol       Date:  2013-10-16

5.  Necrosis- and apoptosis-related Met cleavages have divergent functional consequences.

Authors:  R Montagne; M Berbon; L Doublet; N Debreuck; A Baranzelli; H Drobecq; C Leroy; N Delhem; H Porte; M-C Copin; E Dansin; A Furlan; D Tulasne
Journal:  Cell Death Dis       Date:  2015-05-21       Impact factor: 8.469

6.  Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.

Authors:  Maria J De Herdt; Stefan M Willems; Berdine van der Steen; Rob Noorlag; Esther I Verhoef; Geert J L H van Leenders; Robert J J van Es; Senada KoljenoviÄ; Robert J Baatenburg de Jong; Leendert H J Looijenga
Journal:  Oncotarget       Date:  2016-03-15

7.  Palmitoylation regulates the intracellular trafficking and stability of c-Met.

Authors:  David T Coleman; Alana L Gray; Steven J Kridel; James A Cardelli
Journal:  Oncotarget       Date:  2016-05-31

8.  Accelerating chemoselective peptide bond formation using bis(2-selenylethyl)amido peptide selenoester surrogates.

Authors:  Laurent Raibaut; Marine Cargoët; Nathalie Ollivier; Yun Min Chang; Hervé Drobecq; Emmanuelle Boll; Rémi Desmet; Jean-Christophe M Monbaliu; Oleg Melnyk
Journal:  Chem Sci       Date:  2016-01-11       Impact factor: 9.825

Review 9.  Targeting the oncogenic Met receptor by antibodies and gene therapy.

Authors:  E Vigna; P M Comoglio
Journal:  Oncogene       Date:  2014-06-02       Impact factor: 9.867

Review 10.  Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation.

Authors:  Leonard Girnita; Claire Worrall; Shin-Ichiro Takahashi; Stefan Seregard; Ada Girnita
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.